Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Llama-derived Anti-rotavirus VHH (ARP1) in Children
NCT01259765Phase 2Completed
- Sponsor
- icddr,b
- Start
- Jan 2006
- Primary completion
- Sep 2008
- Modality
- Nanobodies (VHH)
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in rotavirus gastroenteritis comparing VHH (ARP1) with Placebo (2 arms). Primary endpoint: Diarrhoea severity (indicated by reduced stool volume). Started Jan 2006; status: completed.
02
Drugs
ARP1
03
Conditions
rotavirus gastroenteritis
Beyond the preview
Go deeper on NCT01259765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01259765.